PetVivo Taps Top Sales Executive, Skylor Walker, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
Rhea-AI Summary
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) has appointed Skylor Walker as the new field veterinary business development manager for Louisiana and southern Texas. Walker brings significant experience in veterinary sales, previously working with Contura International and ADP. She will focus on expanding sales of PetVivo's flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary injectable medical device for managing osteoarthritis and other musculoskeletal conditions in animals.
Spryng has shown effectiveness in improving medical outcomes for animals with lameness and joint-related afflictions. The product is now used by over 800 veterinary clinics across 50 states, with more than 10,000 Spryng syringes distributed nationwide. This success aligns with the projected growth of the U.S. animal health market, expected to reach $11.3 billion by 2030.
Positive
- Appointment of experienced sales executive Skylor Walker to expand market presence in Louisiana and southern Texas
- Spryng product adoption by over 800 veterinary clinics across 50 states
- Distribution of more than 10,000 Spryng syringes nationwide
- Spryng shown to improve medical outcomes for animals with joint-related afflictions in multiple independent clinical studies
- Alignment with fast-growing U.S. animal health market, projected to reach $11.3 billion by 2030
Negative
- None.
News Market Reaction
On the day this news was published, PETV declined 2.43%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor Walker to the new position of field veterinary business development manager for the entire state of Louisiana and the southern region of Texas.
“Skylor’s experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals,” PetVivo CEO, John Lai. “Her experience with other hydrogel injectable products enables us to prioritize and better address the veterinarians and clinics in our sales pipeline.”
Walker brings to PetVivo significant knowledge and a strong background in the veterinary industry. She previously served as a regional sales manager covering Texas, Oklahoma, New Mexico for Contura International, the maker of ArthramidVet®. Most recently Skylor excelled as an Associate District Manager for ADP. She earned her Bachelor of Science degree in Political Science from Texas A&M University in College Station, Texas.
Walker will focus on expanding sales of PetVivo’s flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary veterinary medical device that is transforming joint health for animals nationwide.
The unique injectable medical device has garnered widespread attention for its effectiveness in the management of osteoarthritis and other musculoskeletal conditions.
In multiple independent clinical studies, Spryng has been shown to improve the medical outcomes of animals suffering from lameness and other joint related afflictions.
By mimicking and reinforcing natural joint cartilage, Spryng represents a highly effective, drug-free option for veterinarians looking for long-term solutions that can improve the mobility and quality of life for equines and companion animals.
“It is amazing how Spryng has revolutionized how veterinarians approach joint health,” said Walker. “I am excited to join the PetVivo sales team with members who each possess vast experience in the development and commercialization of such life-changing medical devices.”
PetVivo recently achieved key major milestones with Spryng, with it now used by more than 800 veterinary clinics across 50 states. This widespread, growing adoption has resulted in the distribution milestone of more than 10,000 Spryng syringes nationwide.
The increasing success of Spryng is reflective of the fast-growing U.S. animal health market, which is projected to double to
For more information about Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.
To learn more about PetVivo as a publicly traded company, contact John Lai of PetVivo at (952) 405-6216 or Ron Both of CMA at (949) 432-7557 or submit your request here.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
ArthramidVet® is a registered trademark of Contura International.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Investor Contact
Ronald Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email contact
Attachment
FAQ
What is PetVivo's stock symbol?
Who did PetVivo appoint as the new field veterinary business development manager?
What is PetVivo's flagship product?
How many veterinary clinics are using Spryng as of September 2024?
How many Spryng syringes have been distributed nationwide?
